Skip to Content Facebook Feature Image

Senators launch a cross-party effort to end stock trading by lawmakers

News

Senators launch a cross-party effort to end stock trading by lawmakers
News

News

Senators launch a cross-party effort to end stock trading by lawmakers

2026-01-15 21:03 Last Updated At:21:11

WASHINGTON (AP) — Two senators from opposite parties are joining forces in a renewed push to ban members of Congress from trading stocks, an effort that has broad public support but has repeatedly stalled on Capitol Hill.

Democratic Sen. Kirsten Gillibrand of New York and Republican Sen. Ashley Moody of Florida on Thursday plan to introduce legislation, first shared with The Associated Press, that would bar lawmakers and their immediate family members from trading or owning individual stocks.

It's the latest in a flurry of proposals in the House and the Senate to limit stock trading in Congress, lending bipartisan momentum to the issue. But the sheer number of proposals has clouded the path forward. Republican leaders in the House are pushing their own bill on stock ownership, an alternative that critics have dismissed as watered down.

“There’s an American consensus around this, not a partisan consensus, that members of Congress and, frankly, senior members of administrations and the White House, shouldn’t be making money off the backs of the American people,” Gillibrand said in an interview with the AP on Wednesday.

Trading of stock by members of Congress has been the subject of ethics scrutiny and criminal investigations in recent years, with lawmakers accused of using the information they gain as part of their jobs — often not known to the public — to buy and sell stocks at significant profit. Both parties have pledged to stop stock trading in Washington in campaign ads, creating unusual alliances in Congress.

In the House, for example, Republican Rep. Anna Paulina Luna of Florida is trying to bypass party leadership and force a vote on her own stock trading bill. Her push with a discharge petition has 79 of the 218 signatures required, the majority of them Democrats.

House Republican leaders are supporting an alternative bill that would prohibit members of Congress and their spouses from buying individual stocks but would not require lawmakers to divest from stocks they already own. It would mandate public notice seven days before a lawmaker sells a stock. The bill advanced in committee on Wednesday, but its prospects are unclear.

Gillibrand and Moody, meanwhile, are introducing a version of a House bill introduced last year by Reps. Chip Roy, a Republican from Texas, and Seth Magaziner, a Democrat from Rhode Island. That proposal, which has 125 cosponsors, would ban members of Congress from buying or selling individual stocks altogether.

Magaziner and other House Democrats, including Rep. Alexandria Ocasio-Cortez of New York, wrote in a joint statement Wednesday that they “are disappointed that the bill introduced by Republican leadership today fails to deliver the reform that is needed.”

The Senate bill from Gillibrand and Moody would give lawmakers 180 days to divest their individual stock holdings after the bill takes effect, while newly elected members would have 90 days from being sworn in to divest. Lawmakers would be prohibited from trading and owning certain other financial assets, including securities, commodities and futures.

“The American people must be able to trust that their elected officials are focused on results for the American people and not focused on profiting from their positions,” Moody wrote in response to a list of questions from the AP.

The legislation would exempt the president and vice president, a carveout likely to draw criticism from some Democrats. Similar objections were raised last year over a bill that barred members of Congress from issuing certain cryptocurrencies but did not apply to the president.

Gillibrand said the president “should be held to the same standard” but described the legislation as “a good place to start.”

“I don’t think we have to allow the perfect to be the enemy of the good,” Gillibrand said. “There’s a lot more I would love to put in this bill, but this is a consensus from a bipartisan basis and a consensus between two bodies of Congress.”

Moody, responding to written questions, wrote that Congress has the “constitutional power of the purse” so it's important that its members don't have “any other interests in mind, financial or otherwise.”

“Addressing Members of Congress is the number one priority our constituents are concerned with,” she wrote.

It remains to be seen if the bill will reach a vote in the Senate. A similar bill introduced by Gillibrand and GOP Sen. Josh Hawley of Missouri in 2023 never advanced out of committee.

Still, the issue has salience on the campaign trail. Moody is seeking election to her first full term in Florida this year after being appointed to her seat when Marco Rubio became secretary of state. Gillibrand chairs the Senate Democrats’ campaign arm.

“The time has come," Gillibrand said. “We have consensus, and there’s a drumbeat of people who want to get this done.”

FILE -Sen. Ashley Moody, R-Fla., speaks during the confirmation hearing before the Senate Judiciary Committee for Kash Patel, President Donald Trump's choice to be director of the FBI, at the Capitol in Washington, Jan. 30, 2025. (AP Photo/Ben Curtis, File)

FILE -Sen. Ashley Moody, R-Fla., speaks during the confirmation hearing before the Senate Judiciary Committee for Kash Patel, President Donald Trump's choice to be director of the FBI, at the Capitol in Washington, Jan. 30, 2025. (AP Photo/Ben Curtis, File)

FILE - Sen. Kirsten Gillibrand, D-N.Y., leaves the Senate chamber after voting on a government funding bill at the Capitol in Washington, March 14, 2025. (AP Photo/J. Scott Applewhite, File)

FILE - Sen. Kirsten Gillibrand, D-N.Y., leaves the Senate chamber after voting on a government funding bill at the Capitol in Washington, March 14, 2025. (AP Photo/J. Scott Applewhite, File)

NEWARK, Del.--(BUSINESS WIRE)--Jan 15, 2026--

QPS Holdings, LLC (QPS), an award-winning contract research organization (CRO) focused on bioanalysis and clinical trials announces the successful implementation of Oracle Argus, a premier pharmacovigilance system designed to support comprehensive safety case management for clinical trials.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115711485/en/

The adoption of the Oracle Argus drug safety platform underscores QPS’s commitment to advancing patient safety, regulatory compliance, and operational excellence across its clients’ clinical drug development programs. Integrating this industry-standard safety platform strengthens QPS’ ability to capture, manage, and report adverse events in accordance with global regulatory requirements.

“Ensuring patient safety and data integrity is at the heart of what we do when conducting clinical trials,” said Derek Grimes, Executive Vice President of QPS. “Oracle Argus provides us with a robust, scalable solution to support the growing needs of our customer’s clinical trial portfolios and the evolving expectations of regulatory authorities worldwide.”

“Oracle Argus provides QPS Holdings, LLC with a trusted, globally recognized drug safety platform that supports compliance with stringent pharmacovigilance standards and regulations, while streamlining end-to-end safety operations and insights at scale,” said Seema Verma, executive vice president and general manager, Oracle Health and Life Sciences. “With our industry-leading solutions, QPS Holdings, LLC can further transform and elevate its safety case management for customers worldwide.”

The deployment of Oracle Argus will enable QPS to:

As the demand for innovative therapies continues to rise, CROs play a critical role in managing both development speed and patient safety. By leveraging the Oracle Argus platform, QPS is well-positioned to deliver on its mission to accelerate pharmaceutical breakthroughs across the globe by delivering custom-built research services.

###

ABOUT QPS HOLDINGS, LLC

QPS is a global, full-service, GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, bioanalysis, preclinical and clinical drug development services. Since 1995, QPS has grown from a small bioanalysis shop into a full-service CRO with 1,200+ employees in the US, Europe, Asia and India. Today, QPS offers expanded pharmaceutical contract R&D services with special expertise in pharmacology, DMPK, toxicology, bioanalysis, translational medicine, PBMC processing, central safety labs, clinical trials, and clinical research services. An award-winning leader focused on bioanalysis and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction, turnkey laboratories, Phase I/II clinical units, and multi-site clinical research services. For more information, visit http://www.qps.com or email info@qps.com.

ABOUT ORACLE ARGUS

Oracle Argus is an industry-leading, trusted solution for processing, analyzing, and reporting adverse event cases originating in pre-market and post-market drugs, biologics, vaccines, devices, and combination products. Oracle has been a Leader in the IDC MarketScape: Worldwide Life Science R&D Pharmacovigilance Technology Solutions and Consulting Services 2025 Vendor Assessment (doc # US53669225, July 2025). To learn more about Oracle’s pharmacovigilance portfolio visit: https://www.oracle.com/life-sciences/safety-solutions/argus-safety-case-management/. Trademarks: Oracle, Java, MySQL and NetSuite are registered trademarks of Oracle Corporation.

Derek Grimes, EVP, Global Head of Clinical Research at QPS Holdings, LLC.

Derek Grimes, EVP, Global Head of Clinical Research at QPS Holdings, LLC.

Recommended Articles